HIN heartware international, inc

upgrade: heartware's to $56 from $50.

  1. 340 Posts.
    lightbulb Created with Sketch. 27
    Thoratec and HeartWare mentioned positively at Canaccord
    Canaccord's LVAD survey indicates better than expected market growth. The firm expects Thoratec (THOR) and HeartWare (HTWR) to grow faster then their estimates and sees upside to Thoratec's Q1 LVAD unit volume. The firm raised Thoratec's price target to $42 from $35 and HeartWare's to $56 from $50. :theflyonthewall.com
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.